Rep. Butler Announces Passage Of Bill To Permit Use Of Investigational Drugs To Treat Terminal Conditions
Rep. Butler Announces Passage of Bill to Permit Use of Investigational Drugs to Treat Terminal Conditions
February 23, 2016
 
[ Jim Butler Home | Jim Butler Press ]
 
 

Today, State Representative Jim Butler (R–Oakwood) announced passage of House Bill 290, which gives terminally ill patients, with the recommendation of their treating physician, the opportunity to access drugs that are still in the trial period with the United States Food and Drug Administration.


House Bill 290, also known as “Right to Try” legislation, will allow Ohioans who are suffering from a terminal illness to have increased access to investigational drugs, biological products, or devices that have passed Phase I of an FDA clinical trial and will remain in ongoing trials.


“I am proud to vote in favor of this legislation today,” said Rep. Butler.  “Life and health are sacred gifts, and people deserve the ability to explore more options to treat critical medical conditions.  Hopefully, in the not-too-distant future, we will begin to see much greater movement toward permanently curing terminal illnesses. In the meantime, people with these devastating diagnoses deserve access to new treatments that offer hope and prolonged survival."


Currently, the FDA offers an expanded access program, which allows terminally ill individuals to access investigational medications. However there are only about 1,000 annual participants and the application process is burdensome.


Under this legislation, patients are eligible to access an investigational drug provided that all approved treatment options have been utilized without satisfactory results. Before beginning treatment, the legislation requires physicians to obtain informed consent and provide treatment information to patients or their legal guardians. Additionally, House Bill 290 provides certain protections for parties that will be involved in the treatment process.


Similar legislation has already been passed in 24 states, with 19 of those states passing the “Right to Try” legislation in their most recent legislative session. This legislation is not a mandate or requirement for doctors to provide their patients with investigational drugs, but instead creates an opportunity not previously available to physicians and patients.


House Bill 290 was sponsored by Representatives Robert Sprague (R-Findlay) and Marlene Anielski (R-Walton Hills) and now goes to the Ohio Senate for further consideration.

 
 
 
  
Featured Posts